Unstimulated Thyroglobulin Testing in Thyroid Cancer Surveillance
Order a serum thyroglobulin (Tg) measurement using a high-sensitivity assay (functional sensitivity <0.2 ng/mL) along with concurrent thyroglobulin antibody (TgAb) testing while the patient remains on levothyroxine therapy with suppressed TSH.
The Test Order
When measuring unstimulated thyroglobulin in a patient on levothyroxine with suppressed TSH, you must order:
- Serum thyroglobulin (Tg) - using a high-sensitivity immunometric assay
- Thyroglobulin antibodies (TgAb) - mandatory concurrent testing
The TgAb measurement is non-negotiable because these antibodies interfere with Tg assays in approximately 25% of differentiated thyroid cancer (DTC) patients, causing false-negative results that can mask disease 1.
Understanding High-Sensitivity Assays
High-sensitivity Tg assays (also called second-generation assays) have functional sensitivities ≤0.1-0.2 ng/mL 1, 2. These assays have revolutionized DTC surveillance because unstimulated Tg values <0.2 ng/mL measured with these sensitive assays have comparable negative predictive value (>95%) to TSH-stimulated Tg values <1-2 ng/mL 1.
This means that in low-risk and intermediate-risk patients with excellent response to therapy, you can verify absence of disease using unstimulated high-sensitivity Tg without requiring TSH stimulation testing 1, 2.
Clinical Context and Timing
The 2019 ESMO guidelines specify that unstimulated Tg should be measured:
- 6-18 months after initial treatment (total thyroidectomy ± radioactive iodine) to assess treatment response 1
- Every 6-24 months during ongoing surveillance, depending on the patient's response category 1
For patients who achieve excellent response (undetectable Tg with negative imaging), subsequent TSH-stimulated testing is not recommended 2. You simply continue monitoring unstimulated Tg levels over time.
Critical Pitfalls to Avoid
Use the same laboratory and assay method for serial measurements. Tg assays lack standardization, and switching between methods introduces variability that can be misinterpreted as disease progression or regression 1. Document which specific assay your laboratory uses.
Never interpret Tg results without checking TgAb. When TgAb is present, the Tg value becomes unreliable due to assay interference 1, 3. In TgAb-positive patients (≈25% of DTC cases), the trend in TgAb concentrations itself serves as a surrogate tumor marker 3.
Ensure TSH is adequately suppressed when measuring "unstimulated" Tg. The patient should be on levothyroxine with TSH maintained at target levels appropriate for their risk category (typically <0.1 mIU/L for high-risk, 0.1-0.5 mIU/L for intermediate-risk, or 0.5-2 mIU/L for low-risk patients) 1.
Interpretation Framework
For patients post-total thyroidectomy with radioactive iodine ablation:
- Unstimulated Tg <0.2 ng/mL with negative TgAb and negative neck ultrasound = Excellent response, continue annual monitoring 1
- Unstimulated Tg 0.2-0.5 ng/mL = May represent thyroid remnant in patients without radioiodine; monitor trend 4
- Rising unstimulated Tg trend = Highly suspicious for recurrence, even if absolute values remain low; warrants imaging 1, 5
Research demonstrates that in low-risk patients not receiving radioiodine ablation, unstimulated Tg typically falls below 0.5 ng/mL by 6 months post-thyroidectomy and remains stable 4. Values persistently above this threshold or showing upward trends require investigation.
When Stimulated Testing Is Still Needed
TSH-stimulated Tg testing (via recombinant human TSH or levothyroxine withdrawal) may still be considered in 1, 2:
- Patients with indeterminate or biochemical incomplete response after additional therapies
- High-risk patients who have not achieved excellent response
- Situations where high-sensitivity assays are unavailable
However, for patients achieving excellent response with undetectable high-sensitivity unstimulated Tg, stimulated testing adds no clinical value and is not recommended 1, 2, 6.